Valuation: HLS Therapeutics Inc.

Market Cap 89.45M 77.52M 73.27M 66.52M 125M 8.58B 125M 875M 338M 4.35B 336M 329M 13.87B P/E 2026 *
-14x
P/E 2027 * -41.3x
Enterprise Value 89.45M 77.52M 73.27M 66.52M 125M 8.58B 125M 875M 338M 4.35B 336M 329M 13.87B EV / Sales 2026 *
1.53x
EV / Sales 2027 * 1.38x
Free-Float
99.45%
Yield 2026 *
-
Yield 2027 * -
1 day-1.47%
1 week+7.47%
Current month+7.47%
1 month+3.33%
3 months-8.20%
6 months-8.41%
Current year-16.39%
1 week 3.7
Extreme 3.7
4.2
1 month 3.56
Extreme 3.56
4.2
Current year 3.56
Extreme 3.56
5.25
1 year 3.56
Extreme 3.56
5.76
3 years 3
Extreme 3
5.76
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 01/05/2023
Director of Finance/CFO 61 26/01/2024
Chief Tech/Sci/R&D Officer 61 01/06/2014
Director TitleAgeSince
Director/Board Member 58 12/03/2018
Chairman 48 22/06/2023
Director/Board Member 65 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
8/9/26 Buy

Compliance Officer

2,000 0.0064%
1/9/26 Buy

Chief Financial Officer

2,000 0.0064%
28/8/26 TaxCompany -2,000 0.0064% -
Change 5-day change 1-year change 3-year change Capi.($)
-1.47%+7.47%-28.04%-19.72% 89.45M
-1.36%-0.49%+27.95%+111.19% 103B
-0.05%-3.11%+56.73%+165.00% 54.08B
-3.47%-5.30%-16.11%+228.95% 21.25B
-0.31%-1.94%-10.57%-9.42% 7.99B
+0.27%-2.67%-37.40%-36.09% 6.87B
+0.26%-5.34%-4.30%+13.28% 6.32B
-0.20%-3.16%-20.33%-31.30% 5.98B
+0.46%+0.42%-3.09%+19.32% 5.01B
+2.08%+3.80%+13.32%+13.24% 3.87B
Average -0.37%-0.77%-2.18%+45.45% 21.49B
Weighted average by Cap. -0.96%-0.83%+24.02%+116.39%

Financials

2026 *2027 *
Net sales 58.44M 50.64M 47.87M 43.45M 81.44M 5.61B 81.93M 571M 221M 2.84B 220M 215M 9.06B 65.03M 56.35M 53.26M 48.35M 90.62M 6.24B 91.17M 636M 246M 3.16B 244M 239M 10.09B
Net income -5.47M -4.74M -4.48M -4.07M -7.62M -525M -7.67M -53.48M -20.67M -266M -20.55M -20.09M -848M -2.16M -1.88M -1.77M -1.61M -3.02M -208M -3.03M -21.17M -8.18M -105M -8.13M -7.95M -336M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
16/09/26 CAD 4.030 -1.47% 1,618
15/09/26 CAD 4.090 -1.45% 241,861
14/09/26 CAD 4.150 +6.41% 54,491
11/09/26 CAD 3.900 +4.56% 144,351
10/09/26 CAD 3.730 -0.53% 30,665
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.892USD
Average target price
5.286USD
Spread / Average Target
+82.80%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!